Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa

Kosuke Kosai; Norihito Kaku; Naoki Uno; Tomomi Saijo; Yoshitomo Morinaga; Yoshifumi Imamura; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara

doi:10.2174/1874285801812010321

Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa

Kosuke Kosai^*, Norihito Kaku, Naoki Uno, Tomomi Saijo, Yoshitomo Morinaga, Yoshifumi Imamura, Hiroo Hasegawa, Taiga Miyazaki, Koichi Izumikawa, Hiroshi Mukae, Katsunori Yanagihara

^*この論文の責任著者

微生物学講座

研究成果: ジャーナルへの寄稿 › コメント/討論

抄録

Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa The Open Microbiology Journal, 2017, 11-92 The correct Table 2 is mentioned below:. Table 2. Univariate and multivariate analyses of risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to imipenem resistance in Pseudomonas aeruginosa. (Table presented) OR, odds ratio; CI, confidence interval; FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase. The original table provided was: Table 2. Proportion of resistant and MBL-producing strains by presence of FQ or AG resistance in imipenemresistant Pseudomonas aeruginosa. (Table presented) Values are expressed as the number (%). FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase 1)Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.

本文言語	英語
ページ（範囲）	321
ページ数	1
ジャーナル	Open Microbiology Journal
巻	12
号	1
DOI	https://doi.org/10.2174/1874285801812010321
出版ステータス	出版済み - 2018

ASJC Scopus 主題領域

免疫学および微生物学一般

文献へのアクセス

10.2174/1874285801812010321

フィンガープリント

「Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Kosai, K., Kaku, N., Uno, N., Saijo, T., Morinaga, Y., Imamura, Y., Hasegawa, H., Miyazaki, T., Izumikawa, K., Mukae, H., & Yanagihara, K. (2018). Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa. Open Microbiology Journal, 12(1), 321. https://doi.org/10.2174/1874285801812010321

@article{023d18b6958d4712a28fafe8b1934ddb,

title = "Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa",

abstract = "Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa The Open Microbiology Journal, 2017, 11-92 The correct Table 2 is mentioned below:. Table 2. Univariate and multivariate analyses of risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to imipenem resistance in Pseudomonas aeruginosa. (Table presented) OR, odds ratio; CI, confidence interval; FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase. The original table provided was: Table 2. Proportion of resistant and MBL-producing strains by presence of FQ or AG resistance in imipenemresistant Pseudomonas aeruginosa. (Table presented) Values are expressed as the number (%). FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase 1)Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.",

author = "Kosuke Kosai and Norihito Kaku and Naoki Uno and Tomomi Saijo and Yoshitomo Morinaga and Yoshifumi Imamura and Hiroo Hasegawa and Taiga Miyazaki and Koichi Izumikawa and Hiroshi Mukae and Katsunori Yanagihara",

note = "Publisher Copyright: {\textcopyright} 2018 Kosai et al.",

year = "2018",

doi = "10.2174/1874285801812010321",

language = "英語",

volume = "12",

pages = "321",

journal = "Open Microbiology Journal",

issn = "1874-2858",

publisher = "Bentham Science Publishers",

number = "1",

}

Kosai, K, Kaku, N, Uno, N, Saijo, T, Morinaga, Y, Imamura, Y, Hasegawa, H, Miyazaki, T, Izumikawa, K, Mukae, H & Yanagihara, K 2018, 'Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa', Open Microbiology Journal, vol. 12, no. 1, pp. 321. https://doi.org/10.2174/1874285801812010321

TY - JOUR

T1 - Risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to carbapenem resistance in pseudomonas aeruginosa

AU - Kosai, Kosuke

AU - Kaku, Norihito

AU - Uno, Naoki

AU - Saijo, Tomomi

AU - Morinaga, Yoshitomo

AU - Imamura, Yoshifumi

AU - Hasegawa, Hiroo

AU - Miyazaki, Taiga

AU - Izumikawa, Koichi

AU - Mukae, Hiroshi

AU - Yanagihara, Katsunori

PY - 2018

Y1 - 2018

N2 - Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa The Open Microbiology Journal, 2017, 11-92 The correct Table 2 is mentioned below:. Table 2. Univariate and multivariate analyses of risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to imipenem resistance in Pseudomonas aeruginosa. (Table presented) OR, odds ratio; CI, confidence interval; FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase. The original table provided was: Table 2. Proportion of resistant and MBL-producing strains by presence of FQ or AG resistance in imipenemresistant Pseudomonas aeruginosa. (Table presented) Values are expressed as the number (%). FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase 1)Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.

AB - Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas Aeruginosa The Open Microbiology Journal, 2017, 11-92 The correct Table 2 is mentioned below:. Table 2. Univariate and multivariate analyses of risk factors for acquisition of fluoroquinolone or aminoglycoside resistance in addition to imipenem resistance in Pseudomonas aeruginosa. (Table presented) OR, odds ratio; CI, confidence interval; FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase. The original table provided was: Table 2. Proportion of resistant and MBL-producing strains by presence of FQ or AG resistance in imipenemresistant Pseudomonas aeruginosa. (Table presented) Values are expressed as the number (%). FQs, fluoroquinolones; AGs, aminoglycosides; MBL, metallo-B-lactamase 1)Minimum inhibitory concentrations (MICs) for piperacillin, ceftazidime, ciprofloxacin, gentamicin and amikacin were not measured in eleven, one, one, one, and thirteen strains, respectively.

UR - http://www.scopus.com/inward/record.url?scp=85055796031&partnerID=8YFLogxK

U2 - 10.2174/1874285801812010321

DO - 10.2174/1874285801812010321

M3 - コメント/討論

C2 - 30369989

AN - SCOPUS:85055796031

SN - 1874-2858

VL - 12

SP - 321

JO - Open Microbiology Journal

JF - Open Microbiology Journal

IS - 1

ER -